We provided a distinct and HCC-specific mechanism of AXL-driven tumor-intrinsic signaling to promote an immunosuppressive phenotype of TKI-resistant HCC and further proposed the application of AXL targeting to overcome a potential cross-resistance in HCC. The gene discussed is AXL; the disease is neoplasm.